Cargando…

Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma

BACKGROUND: Cyclin-dependent kinase subunit 2 (CKS2) is a member of cyclin dependent kinase subfamily and the relationship between CKS2 and osteosarcoma (OS) remains to be further analyzed. METHODS: 80 OS and 41 non-tumor tissue samples were arranged to perform immunohistochemistry (IHC) to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Chaohua, Wu, Yanxing, Ma, Jie, Xie, Le, Huang, Yingxin, Xu, Yuanyuan, Peng, Huizhi, Chen, Zengwei, Zeng, Min, Mao, Rongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004629/
https://www.ncbi.nlm.nih.gov/pubmed/35410253
http://dx.doi.org/10.1186/s12920-022-01234-8
_version_ 1784686306461220864
author Mo, Chaohua
Wu, Yanxing
Ma, Jie
Xie, Le
Huang, Yingxin
Xu, Yuanyuan
Peng, Huizhi
Chen, Zengwei
Zeng, Min
Mao, Rongjun
author_facet Mo, Chaohua
Wu, Yanxing
Ma, Jie
Xie, Le
Huang, Yingxin
Xu, Yuanyuan
Peng, Huizhi
Chen, Zengwei
Zeng, Min
Mao, Rongjun
author_sort Mo, Chaohua
collection PubMed
description BACKGROUND: Cyclin-dependent kinase subunit 2 (CKS2) is a member of cyclin dependent kinase subfamily and the relationship between CKS2 and osteosarcoma (OS) remains to be further analyzed. METHODS: 80 OS and 41 non-tumor tissue samples were arranged to perform immunohistochemistry (IHC) to evaluate CKS2 expression between OS and non-tumor samples. The standard mean deviation (SMD) was calculated based on in-house IHC and tissue microarrays, and exterior high-throughput datasets for further verification of CKS2 expression trend in OS. The effect of CKS2 expression on clinicopathological parameters of OS patients, and single-cell in OS tissues was analyzed through public high-throughput datasets and functional enrichment analysis was conducted for co-expression genes of CKS2 in accordance with weighted correlation network analysis. RESULTS: A total of 217 OS samples and 87 non-tumor samples (including tissue and cell line) were obtained from in-house IHC, microarrays and exterior high-throughput datasets. The analysis of integrated expression status demonstrated up-regulation of CKS2 in OS (SMD = 1.57, 95%CI [0.27–2.86]) and the significant power of CKS2 expression in distinguishing OS samples from non-tumor samples (AUC = 0.97 95%CI [0.95–0.98]). Clinicopathological analysis of GSE21257 indicated that OS patients with higher CKS2 expression was more likely to suffer OS metastasis. Although Kaplan–Meier curves showed no remarkable difference of overall survival rate between OS patients with high and low-CKS2, CKS2 was found up-regulated in proliferating osteosarcoma cells. Co-expression genes of CKS2 were mainly assembled in function and pathways such as cell cycle, cell adhesion, and intercellular material transport. CONCLUSIONS: In summary, up-regulation of CKS2 expression in OS tissue was found through multiple technical approaches. In addition, scRNA-seq and co-expression analysis showed that CKS2 may have an impact on important biological process linked with cell cycle, cell adhesion, and intercellular material transport. Present study on CKS2 in OS indicated a promising prospect for CKS2 as a biomarker for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-022-01234-8.
format Online
Article
Text
id pubmed-9004629
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90046292022-04-13 Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma Mo, Chaohua Wu, Yanxing Ma, Jie Xie, Le Huang, Yingxin Xu, Yuanyuan Peng, Huizhi Chen, Zengwei Zeng, Min Mao, Rongjun BMC Med Genomics Research BACKGROUND: Cyclin-dependent kinase subunit 2 (CKS2) is a member of cyclin dependent kinase subfamily and the relationship between CKS2 and osteosarcoma (OS) remains to be further analyzed. METHODS: 80 OS and 41 non-tumor tissue samples were arranged to perform immunohistochemistry (IHC) to evaluate CKS2 expression between OS and non-tumor samples. The standard mean deviation (SMD) was calculated based on in-house IHC and tissue microarrays, and exterior high-throughput datasets for further verification of CKS2 expression trend in OS. The effect of CKS2 expression on clinicopathological parameters of OS patients, and single-cell in OS tissues was analyzed through public high-throughput datasets and functional enrichment analysis was conducted for co-expression genes of CKS2 in accordance with weighted correlation network analysis. RESULTS: A total of 217 OS samples and 87 non-tumor samples (including tissue and cell line) were obtained from in-house IHC, microarrays and exterior high-throughput datasets. The analysis of integrated expression status demonstrated up-regulation of CKS2 in OS (SMD = 1.57, 95%CI [0.27–2.86]) and the significant power of CKS2 expression in distinguishing OS samples from non-tumor samples (AUC = 0.97 95%CI [0.95–0.98]). Clinicopathological analysis of GSE21257 indicated that OS patients with higher CKS2 expression was more likely to suffer OS metastasis. Although Kaplan–Meier curves showed no remarkable difference of overall survival rate between OS patients with high and low-CKS2, CKS2 was found up-regulated in proliferating osteosarcoma cells. Co-expression genes of CKS2 were mainly assembled in function and pathways such as cell cycle, cell adhesion, and intercellular material transport. CONCLUSIONS: In summary, up-regulation of CKS2 expression in OS tissue was found through multiple technical approaches. In addition, scRNA-seq and co-expression analysis showed that CKS2 may have an impact on important biological process linked with cell cycle, cell adhesion, and intercellular material transport. Present study on CKS2 in OS indicated a promising prospect for CKS2 as a biomarker for OS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-022-01234-8. BioMed Central 2022-04-11 /pmc/articles/PMC9004629/ /pubmed/35410253 http://dx.doi.org/10.1186/s12920-022-01234-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Mo, Chaohua
Wu, Yanxing
Ma, Jie
Xie, Le
Huang, Yingxin
Xu, Yuanyuan
Peng, Huizhi
Chen, Zengwei
Zeng, Min
Mao, Rongjun
Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
title Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
title_full Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
title_fullStr Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
title_full_unstemmed Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
title_short Clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
title_sort clinicopathological value of the upregulation of cyclin-dependent kinases regulatory subunit 2 in osteosarcoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004629/
https://www.ncbi.nlm.nih.gov/pubmed/35410253
http://dx.doi.org/10.1186/s12920-022-01234-8
work_keys_str_mv AT mochaohua clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT wuyanxing clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT majie clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT xiele clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT huangyingxin clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT xuyuanyuan clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT penghuizhi clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT chenzengwei clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT zengmin clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma
AT maorongjun clinicopathologicalvalueoftheupregulationofcyclindependentkinasesregulatorysubunit2inosteosarcoma